| Literature DB >> 34937243 |
R Neena1, Anjana Gopan2, Ayshathu Nasheetha2, Anantharaman Giridhar3.
Abstract
PURPOSE: To analyze whether photoscreening can effectively detect amblyogenic risk factors in children with neurodevelopmental disability.Entities:
Keywords: Amblyogenic risk factors; neurodevelopmental disability; photoscreening; spot®vision screener
Mesh:
Year: 2022 PMID: 34937243 PMCID: PMC8917574 DOI: 10.4103/ijo.IJO_672_21
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Figure 1Welch Allyn spot vision screener: model VS100 (Spot)
Amblyopia risk factors targeted with automated preschool vision screening
| Age, months | Refractive risk factor targetsa | |||
|---|---|---|---|---|
|
| ||||
| Astigmatism | Hyperopia | Anisometropia | Myopia | |
| 12-30 | >2.0 D | >4.5 D | >2.5 D | >-3.5 D |
| 31-48 | >2.0 D | >4.0 D | >2.0 D | >-3.0 D |
| >48 | >1.5 D | >3.5 D | >1.5 D | >-1.5 D |
| All ages | Nonrefractive amblyopia risk factor targetsb | |||
D, dioptres; PD, prism dioptres. aAdditional reporting of sensitivity to detect greater-magnitude refractive errors is encouraged. bFor all ages.
Figure 2Type of neurodevelopmental disability detected
Figure 3Distribution of amblyogenic risk factors
Amblyogenic risk factor detection
| Spot® Judgement | Clinical Evaluation | Total | |
|---|---|---|---|
|
| |||
| Clinical evaluation: Fail | Clinical evaluation: Pass | ||
| Spot® Judgment: Fail | 28 | 7 | 35 |
| Spot® Judgment: Pass | 1 | 12 | 13 |
| Could not detect | 3 | 1 | 4 |
| Total | 32 | 20 | 52 |
SPOT® vs clinical evaluation: Out of the 32 subjects who failed in the clinical evaluation, 28 were failed, 1 passed, and in 3, no report could be given by the Spot. Out of the 20 who passed the clinical examination, 7 were failed, 12 passed, and in 1, no report could be given by the Spot
Sensitivity and specificity of SPOT® in amblyogenic risk factor detection*
| Parameter | Area Under Curve | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
|---|---|---|---|---|---|
| Spot® Vision | 0.799 | 96.50 | 63.61 | 80.00 | 92.31 |
*4 children in “Could not detect” group were not included
Figure 4Types of refractive error detected
Figure 5Spherical equivalent of Right eye and Left eye across two groups
Figure 6Average spherical equivalent across two groups
Squint detection
| Spot®: Squint Detection | Clinical Evaluation: Squint Detection | Total | |
|---|---|---|---|
|
| |||
| Yes | No | ||
| Yes | 15 | 0 | 15 |
| No | 7 | 26 | 33 |
| Could not detect | 2 | 2 | 4 |
| Total | 24 | 28 | 52 |
SPOT vision vs clinical evaluation: Out of the 24 subjects who were confirmed to have squint (Yes) by clinical evaluation, 15 were detected to have squint, 7 were not detected to have squint and in 2, no report could be given by the Spot. Similarly, out of the 28 subjects confirmed to have no squint (No) in the clinical evaluation, 26 were cleared by Spot and in 2, no report could be given by the Spot
Sensitivity and specificity of SPOT® in squint detection**
| Parameter | Area Under Curve | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
|---|---|---|---|---|---|
| Squint Detection | 0.841 | 68.18 | 100 | 100 | 78.79 |
**Could not detect” was not included
Comparison with other published studies
| No of patients | Average age | Amblyogenic Risk Factor | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value | |
|---|---|---|---|---|---|---|---|
| Marzolf[ | 100 | 5.7 | 38% | 84% | 62% | 58% | 86% |
| Our study | 52 | 10.5 | 73.1% | 96.5% | 63.61% | 80% | 92.31% |